Save Meropenem/Vaborbactam for Carbapenem-Resistant Enterobacteriaceae
December 2017
Meropenem/vaborbactam (Vabomere, VAY-boh-meer) will be the first antibiotic to combine a carbapenem with a beta-lactamase inhibitor.
Adding the beta-lactamase inhibitor vaborbactam helps meropenem outsmart carbapenem-resistant superbugs, which cause about 9,000 infections in the U.S. each year.
Meropenem/vaborbactam is approved to treat complicated urinary tract infections (UTIs), including pyelonephritis. Early evidence suggests it's also effective for bacteremia, pneumonia, and intra-abdominal infections.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote